A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)
Status:
Terminated
Trial end date:
2016-08-03
Target enrollment:
Participant gender:
Summary
The purpose of the study is to see whether BMN053 is safe and effective to use as medication
for Duchenne muscular dystrophy (DMD) patients with a mutation around location 53 in the DNA
for the dystrophin protein.